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AbstrAct
Inclusion of patient-reported outcomes is important in 
SLE clinical trials as they allow capture of the benefits 
of a proposed intervention in areas deemed pertinent 
by patients. We aimed to compare the measurement 
properties of health-related quality of life (HRQoL) 
measures used in adults with SLE and to evaluate their 
responsiveness to interventions in randomised controlled 
trials (RCTs). A systematic review was undertaken using full 
original papers in English identified from three databases: 
MEDLINE, EMBASE and PubMed. Studies describing the 
validation of HRQoL measures in English-speaking adult 
patients with SLE and SLE drug RCTs that used an HRQoL 
measure were retrieved. Twenty-five validation papers and 
26 RCTs were included in the indepth review evaluating the 
measurement properties of 4 generic (Medical Outcomes 
Study Short-Form 36 (SF36), Patient Reported Outcomes 
Measurement Information System (PROMIS) item-bank, 
EuroQol-5D, and Functional Assessment of Chronic Illness 
Therapy-Fatigue) and 3 disease-specific (Lupus Quality 
of Life (LupusQoL), Lupus Patient Reported Outcomes, 
Lupus Impact Tracker (LIT)) instruments. All measures 
had good convergent and discriminant validity. PROMIS 
provided the strongest evidence for known-group validity 
and reliability among generic instruments; however, data 
on its responsiveness have not been published. Across 
measures, standardised response means were generally 
indicative of poor-moderate sensitivity to longitudinal 
change. In RCTs, clinically important improvements 
were reported in SF36 scores from baseline; however, 
between-arm differences were frequently non-significant 
and non-important. SF36, PROMIS, LupusQoL and LIT 
had the strongest evidence for acceptable measurement 
properties, but few measures aside from the SF36 have 
been incorporated into clinical trials. This review highlights 
the importance of incorporating a broader range of SLE-
specific HRQoL measures in RCTs and warrants further 
research that focuses on longitudinal responsiveness of 
newer instruments.
IntroduCtIon
SLE is a chronic inflammatory autoimmune 
disorder with variable multisystem involve-
ment, an unpredictable relapsing–remitting 
course, an early onset and a significant impact 
on health-related quality of life (HRQoL).1 
Previous research has shown poor correla-
tion between HRQoL and physician assess-
ments of disease activity and damage, high-
lighting the distinct contribution of HRQoL 
data to understanding patient trajectories 
and supporting the need for its assessment in 
SLE.2 Further, HRQoL has been found to be 
an important determinant of adherence and 
healthcare utilisation in patients with SLE 
and may facilitate justifying the considerable 
costs of new therapies.3 Therefore, both the 
US Food and Drug Administration and the 
European Medicines Agency advocate use of 
patient-reported instruments such as those 
measuring HRQoL in clinical trials (guide-
lines available at  fda. gov and  ema. europa. eu, 
respectively).
Patient-reported HRQoL measures, in 
the form of questionnaires, have been 
either developed exclusively for use in SLE 
(disease-specific measures) or have been used 
in patients with SLE but developed for any 
disease state or healthy individuals (generic 
measures). Patient-reported outcome eval-
uation has been incorporated in drug clin-
ical trials in SLE; however, it has not been 
a consistent practice,4 and it is not clear 
whether sensitivity to change over time has 
been observed.5 6 Knowledge of acceptable 
measurement standards, responsiveness to 
change, generalisability and cultural adapt-
ability would help determine the adequacy of 
the HRQoL measure for clinical research.
The aims of this systematic review were (1) 
to compare the measurement properties of 
published HRQoL measures that have been 
developed and/or evaluated for use in adults 
with SLE and (2) to evaluate the responsive-
ness of validated HRQoL measures used in 
SLE randomised controlled trials (RCTs) to 
date. Our goal was to provide a comprehen-
sive review of these outcome measures to 
inform future selection of these tools in SLE 
clinical trials.
Methods
search strategy
Literature searches were conducted in 
MEDLINE, EMBASE and PubMed, limited 
to humans, English language and articles 
published between inception and 1 April 
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2018. Journal articles (excluding conference abstracts, 
letters to editor, dissertations and book chapters) 
containing the keywords in the title and/or abstract were 
included (search terms are available in online supple-
mentary material 1).
For our first aim, we included papers that described 
the methodology of the development and validation of 
HRQoL measures in SLE, and papers that described the 
evaluation of an existing HRQoL measure or its trans-
lated/adapted version for patients with SLE. Exclusion 
criteria were inadequate numbers of patients with SLE 
(<50% of the study population) and patients <18 years 
old. For our second aim, we included drug RCTs (pilot 
studies, phase I, II and III) in patients with SLE with 
published HRQoL data. Exclusion criteria were trans-
plantation or plasma exchange RCTs, cutaneous lupus 
RCTs and RCTs in patients <18 years old.
The selected articles were categorised into (1) valida-
tion studies of extensively published HRQoL instruments 
(defined as having >3 validation studies in English-
speaking SLE populations) and HRQoL instruments that 
had been used in an RCT, and (2) RCTs that used a vali-
dated HRQoL instrument.
outcomes
Measurement properties
To assess measurement properties, we evaluated floor and 
ceiling effects, construct validity, test–retest reliability, 
internal consistency, and responsiveness. The instrument 
was considered to have floor or ceiling effects if >15% of 
the respondents scored at the extreme ends of the scale.7 
Construct validity was determined using convergent and 
discriminant validity and known-group validity. Conver-
gent validity was judged to be adequately demonstrated 
if there were high (>0.6) positive correlations between 
scales and discriminant validity, if correlations were low 
(<0.3) or if they were negative.8 Known-group validity was 
adequate if group means differed by ≥0.5 SD.9 Test–retest 
reliability was gauged by the intraclass correlation coeffi-
cient (ICC) and considered adequate if ICC was >0.7.10 
The acceptable statistical value for internal consistency 
was a Cronbach’s α >0.7.10 Responsiveness was compared 
using standardised response means (SRMs) and consid-
ered poor if SRMs were <0.5, moderate if SRMs were 
≥0.5 and high if SRMs were ≥0.8.11 The generalisability 
of the instrument was assessed by establishing if the study 
population was adequately described to help investigators 
extrapolate the results to their study cohorts. For each 
measure, we also determined if estimates of SLE-specific 
minimally important differences (MID) were available. 
While our review focused on English-speaking popula-
tions, we noted the availability of validation studies in 
non-English-speaking populations for each measure.
Responsiveness to interventions in RCTs
The results of any intervention during RCTs were inter-
preted in the context of the MID value of the instrument 
being used. We first determined if the direction of change 
in HRQoL scale was consistent with clinical changes meas-
ured by disease activity, damage or flare indices. We then 
determined if between-arm differences in HRQoL were 
≥MID. Finally, we determined if HRQoL changes from 
baseline were ≥MID.
screening process and data extraction
Screening and data extraction were performed by two 
independent researchers using predesigned templates 
and in line with the Centre for Reviews and Dissemina-
tion guidance, available at  york. ac. uk/ crd. Any disagree-
ments were discussed and resolved based on consensus 
opinion. In addition to the outcomes, demographics, 
clinical data and information on instrument characteris-
tics were extracted.
After removal of duplicates, screening of titles and 
abstracts, and full-text review, 23 validation studies in 
English-speaking patients with SLE that met the inclu-
sion criteria were identified and were selected for the 
indepth review (figure 1). Of the 23 studies, 21 focused 
on 5 HRQoL instruments (the Medical Outcomes Study 
Short-Form 36 (SF36), the Patient Reported Outcomes 
Measurement Information System item-bank (PROMIS), 
the Lupus Quality of Life (LupusQoL), the Lupus Patient 
Reported Outcomes and the Lupus Impact Tracker 
(LIT)) and 2 papers described the validation of the 
Functional Assessment of Chronic Illness Therapy-Fa-
tigue (FACIT-Fatigue) and EuroQoL-5D (EQ5D). The 
references of the selected 23 papers were also screened 
for additional relevant papers and 2 further papers were 
identified and included in the review. We excluded 25 
studies that described the measurement properties of 
22 additional HRQoL instruments not used in an RCT 
setting, with 1–3 studies per instrument (list available in 
online supplementary material 1).
After removal of duplicates, screening of title and 
abstracts, and full-text review, 26 papers describing an 
RCT in SLE with HRQoL data were identified. HRQoL 
instruments used included the SF36 (25 papers), EQ5D 
(1 paper) and FACIT-Fatigue (3 papers). The references 
of the selected 26 papers were also screened for additional 
relevant papers and no further papers were identified.
results
Table 1 provides information on demographics and clin-
ical characteristics of participants with SLE in patient-re-
ported outcome validation studies. Information on 
instrument characteristics is provided in table 2. Meas-
urement properties are summarised in table 3, and data 
on measure responsiveness from RCTs are summarised in 
table 4.
Medical outcomes study short-Form 36
We found only one study that reported the frequency 
of maximum and minimum obtainable scores; role 
emotional and role physical domains were found to have 
significant floor and ceiling effects.12 The instrument 
had good internal consistency; however, its test–retest 
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Figure 1 Of the 25 validation papers identified, 8 assessed the measurement properties of Short-Form 36, 1 assessed 
EuroQoL-5D, 7 assessed Lupus Quality of Life questionnaire, 5 assessed Patient Reported Outcomes Measurement Information 
System item-bank, 3 assessed Lupus Patient Reported Outcomes questionnaire, 6 assessed Lupus Impact Tracker, and 1 
assessed Functional Assessment of Chronic Illness Therapy-Fatigue. Some studies assessed multiple quality of life instruments. 
*Extensively published defined as having >3 validation studies in English-speaking SLE populations or having been used in 
an RCT. Of the 26 RCT papers identified, 25 used Short-Form 36, 3 used Functional Assessment of Chronic Illness Therapy-
Fatigue and 1 used EuroQol-5D. Some studies used >2 quality of life instruments. PRO, patient-reported outcome; RCT, 
randomised controlled trial.
reliability using ICC is currently unknown.13 14 The 
Health Assessment Questionnaire scores correlated 
strongly with the SF36 physical function scores (r=0.75) 
and moderately with role physical, bodily pain and 
vitality scores (r=0.41–0.48).15 Weak-moderate corre-
lations (r≤0.41) were reported with various disease 
activity or damage indices.12–15 The mean SF36 scores 
differed significantly across categories of disease 
activity; however, the effect size was not reported.13 16 
Studies examining responsiveness were inconsistent in 
the methodology but seem to suggest that the measure 
is not particularly responsive in SLE. SRMs were poor 
in most domains and inconsistent (poor to moderate) 
across different anchors.17 18 SLE-specific MIDs have 
been reported using anchor-based and distribu-
tions-based methods. Anchor-based MIDs for improve-
ment ranged from 2.8 to 10.9 for domains and from 
2.1 to 2.4 for summary scores, which is consistent with 
literature-reported estimates from other rheumatolog-
ical conditions (5–10 points for domains and 2.5–5 
for summary scores).17 18 Validation studies using the 
Chinese, French and Turkish versions of the SF36 have 
shown results that are comparable with the English 
version.19–22
In RCTs, we assessed responsiveness in two ways. First, we 
determined if between-arm differences met or exceeded 
the commonly accepted MID (5–10 points for domains 
and 2.5–5 for summary scores). Then we determined if 
improvements over time (from baseline) were ≥MID. We 
found that although SF36 scores generally improved over 
time, between-arm differences were clinically non-im-
portant, implying that the SF36 is not responsive to inter-
ventions.23–48 Among 10 studies that met the primary 
efficacy endpoint and had sufficient data for analysis, 6 
reported improvements in SF36 scores from baseline that 
were ≥MID (table 4), while only 2 reported between-arm 
differences in SF36 scores that were ≥MID in all or most 
domains. Within-arm improvements from baseline were 
not limited to RCTs that achieved the primary efficacy 
endpoint. Improvements in SF36 scores from baseline 
were also ≥MID in 6 of 10 RCTs that reported a statisti-
cally non-significant clinical improvement.
Izadi Z, et al. Lupus Science & Medicine 2018;5:e000279. doi:10.1136/lupus-2018-0002794
Lupus Science & Medicine
Ta
b
le
 1
 
D
em
og
ra
p
hi
cs
 a
nd
 c
lin
ic
al
 c
ha
ra
ct
er
is
tic
s 
of
 p
ar
tic
ip
an
ts
 w
ith
 S
LE
 in
 p
at
ie
nt
-r
ep
or
te
d
 o
ut
co
m
e 
va
lid
at
io
n 
st
ud
ie
s
M
ea
su
re
Fi
rs
t 
au
th
o
r 
an
d
 y
ea
r
C
it
at
io
n
P
at
ie
nt
s 
in
 t
he
 
st
ud
y 
(n
)
Fe
m
al
e,
 n
 
(%
)
A
g
e 
in
 y
ea
rs
, m
ea
n 
(S
D
)
S
LE
 d
is
ea
se
 d
ur
at
io
n 
in
 
ye
ar
s,
 m
ea
n 
(S
D
)
D
is
ea
se
 a
ct
iv
it
y,
 
m
ed
ia
n 
(r
an
g
e)
D
is
ea
se
 d
am
ag
e,
 
m
ed
ia
n 
(r
an
g
e)
S
F3
6
N
an
te
s 
20
18
12
9
78
N
S
 (9
0)
39
.2
 (1
3.
3)
11
.9
 (7
.6
)
S
LE
D
A
I 9
.7
 (4
.8
)*
S
D
I 1
.7
 (1
.6
)*
S
to
ll 
19
97
13
10
15
0
14
3 
(9
5)
40
 (1
1.
0)
10
 (7
)
B
IL
A
G
 5
 (3
–7
)
S
LI
C
C
 1
 (0
–2
)
Th
um
b
oo
 1
99
91
4
11
11
8
11
2 
(9
4.
5)
N
S
3.
61
 (0
.0
1–
16
.1
)
B
IL
A
G
 2
 (0
–1
5)
S
LI
C
C
 0
 (0
–8
)
Fo
rt
in
 1
99
81
5
12
96
N
S
 (9
0)
36
 (2
8–
46
)†
15
 (1
0–
19
)†
S
LE
D
A
I 6
.2
 (6
.4
)*
S
LI
C
C
 1
.2
9 
(1
.6
2)
*
S
ab
a 
20
03
16
13
21
9
N
S
 (9
4.
4)
45
 (N
S
)
N
S
m
-S
LA
M
 4
 (0
–1
7)
‡
N
S
To
um
a 
20
11
59
14
41
37
 (N
S
)
45
.3
 (1
3.
2)
14
.8
 (1
0.
3)
S
LE
D
A
I 2
.5
9 
(2
.4
1)
N
S
M
cE
lh
on
e 
20
16
17
 
15
10
1
95
 (9
4)
40
.9
 (1
2.
8)
9.
3 
(8
.1
)
B
IL
A
G
 1
6.
4 
(8
.1
)*
S
LI
C
C
 0
.5
6 
(1
.1
8)
*
C
ol
an
ge
lo
 2
00
91
8
16
20
2
N
S
 (9
4)
50
 (1
4)
10
 (7
.4
)
S
LE
D
A
I 6
.1
 (4
.7
)*
S
LI
C
C
 1
.4
 (1
.7
)*
E
Q
5D
A
gg
ar
w
al
 2
00
95
5
54
16
7
15
6 
(9
3.
5)
42
.5
 (1
3.
0)
9.
3 
(8
.8
)
S
LE
D
A
I 6
.2
 (5
.7
)*
S
LI
C
C
 2
 (2
)
FA
C
IT
-F
at
ig
ue
La
i 2
01
15
4
52
25
4
23
2 
(9
0.
9)
40
.3
 (1
1.
9)
N
S
N
S
N
S
P
R
O
M
IS
K
as
tu
ri 
20
17
50
48
20
4
N
S
 (9
3)
40
.0
 (1
3.
2)
12
.2
 (8
.8
)
S
LE
D
A
I 4
.2
 (3
.5
)*
S
D
I 1
.2
 (1
.7
)*
K
as
tu
ri 
20
18
51
49
20
4
N
S
 (9
3)
40
.0
 (1
3.
2)
12
.2
 (8
.8
)
S
LE
D
A
I 4
.2
 (3
.5
)*
S
D
I 1
.2
 (1
.7
)*
K
at
z 
20
17
49
47
24
0
21
9 
(9
1)
58
 (1
3)
22
 (1
2)
S
LA
Q
 1
08
*
N
S
La
i 2
01
75
3
51
33
3
30
5 
(9
1.
6)
44
.7
 (1
2.
5)
12
.3
 (9
.6
)
N
S
N
S
M
ah
ie
u 
20
16
50
12
3
11
6 
(9
4.
3)
45
.3
 (1
0.
8)
N
S
S
LE
D
A
I 2
.3
 (2
.8
)*
S
LI
C
C
 1
.7
 (2
.2
)*
Lu
p
us
Q
oL
M
cE
lh
on
e 
20
07
58
57
16
0
15
2 
(9
5)
45
.3
 (1
3.
9)
N
S
N
S
N
S
M
cE
lh
on
e 
20
10
61
60
32
2
25
7 
(N
S
)
45
.0
 (1
3.
4)
10
.5
 (8
.6
)
N
S
S
LI
C
C
 0
.7
5 
(1
.2
5)
*
N
an
te
s 
20
18
12
9
78
N
S
 (9
0)
39
.2
 (1
3.
3)
11
.9
 (7
.6
)
S
LE
D
A
I 9
.7
 (4
.8
)*
S
D
I 1
.7
 (1
.6
)*
D
ev
ill
ie
rs
 2
01
75
7
56
29
5
N
S
 (9
0)
42
 (1
7–
75
)‡
N
S
S
LE
D
A
I 4
 (2
–6
)
N
S
To
um
a 
20
11
59
14
41
37
 (N
S
)
45
.3
 (1
3.
2)
14
.8
 (1
0.
3)
S
LE
D
A
I 2
.5
9 
(2
.4
1)
N
S
M
cE
lh
on
e 
20
16
17
 
15
10
1
95
 (9
4)
40
.9
 (1
2.
8)
9.
3 
(8
.1
)
B
IL
A
G
 1
6.
4 
(8
.1
)*
S
LI
C
C
 0
.5
6 
(1
.1
8)
*
Jo
lly
 2
01
06
0
59
18
6
N
S
 (9
4)
42
.5
 (1
2.
9)
N
S
S
LE
D
A
I 6
.2
 (5
.8
)*
S
LI
C
C
 2
.0
 (2
.1
)*
Lu
p
us
P
R
O
Jo
lly
 2
01
27
1
71
32
3
N
S
 (9
3)
45
.1
 (1
2.
3)
9.
3 
(7
.6
)
S
LE
D
A
I 3
.9
 (3
.8
)*
S
D
I 0
.7
 (1
.1
)*
A
zi
zo
d
d
in
 2
01
77
3
72
13
7
12
4 
(9
0.
5)
40
.4
 (1
4.
1)
8.
13
 (6
.8
4)
S
LE
D
A
I 4
.8
9(
4.
43
)*
S
D
I 0
.6
1 
(1
.0
5)
*
B
ou
rr
é-
Te
ss
ie
r 
20
14
74
73
12
3
N
S
 (9
4)
47
.7
 (1
4.
8)
N
S
S
LE
D
A
I 4
.0
 (6
.0
)†
S
D
I 1
.0
 (3
.0
)†
LI
T
Jo
lly
 2
01
48
4
83
30
8
N
S
 (9
3)
43
.3
 (1
3.
3)
N
S
S
LE
D
A
I 3
.9
 (3
.8
)*
N
S
Jo
lly
 2
01
68
3
82
32
5
N
S
 (9
0)
41
.9
 (1
3)
N
S
S
LE
D
A
I 4
.2
8 
(3
.8
)*
S
LI
C
C
 2
.1
7 
(1
.5
9)
*
G
ia
ng
re
co
 2
01
58
7
86
18
2
17
0 
(9
3)
43
.5
 (1
3.
2)
N
S
S
LE
D
A
I 6
.4
 (7
.3
)*
N
S
A
nt
on
y 
20
17
85
84
73
N
S
 (9
0)
41
 (1
9–
74
)‡
N
S
S
LE
D
A
I 4
 (0
–1
6)
‡
S
D
I 1
 (0
–6
)‡
B
ra
nd
t 
20
17
86
85
86
0
80
7 
(9
3.
8)
45
.8
 (1
3.
4)
13
.4
 (9
.2
)
S
LA
Q
 1
7.
2 
(9
.4
)*
N
S
D
ev
ill
ie
rs
 2
01
75
7
56
29
5
N
S
 (9
0)
42
 (1
7–
75
)‡
N
S
S
LE
D
A
I 4
 (2
–6
)
N
S
C
on
tin
ue
d
Izadi Z, et al. Lupus Science & Medicine 2018;5:e000279. doi:10.1136/lupus-2018-000279 5
Review
M
ea
su
re
Fi
rs
t 
au
th
o
r 
an
d
 y
ea
r
C
it
at
io
n
P
at
ie
nt
s 
in
 t
he
 
st
ud
y 
(n
)
Fe
m
al
e,
 n
 
(%
)
A
g
e 
in
 y
ea
rs
, m
ea
n 
(S
D
)
S
LE
 d
is
ea
se
 d
ur
at
io
n 
in
 
ye
ar
s,
 m
ea
n 
(S
D
)
D
is
ea
se
 a
ct
iv
it
y,
 
m
ed
ia
n 
(r
an
g
e)
D
is
ea
se
 d
am
ag
e,
 
m
ed
ia
n 
(r
an
g
e)
*m
ea
n 
(S
D
).
†m
ed
ia
n 
(IQ
R
).
‡m
ea
n 
(r
an
ge
).
B
IL
A
G
, B
rit
is
h 
Is
le
s 
Lu
p
us
 A
ss
es
sm
en
t 
G
ro
up
 D
is
ea
se
 A
ct
iv
ity
 In
d
ex
; E
Q
5D
, E
ur
oQ
ol
-5
D
; F
A
C
IT
-F
at
ig
ue
, F
un
ct
io
na
l A
ss
es
sm
en
t 
of
 C
hr
on
ic
 Il
ln
es
s 
Th
er
ap
y-
Fa
tig
ue
; L
IT
, L
up
us
 Im
p
ac
t 
Tr
ac
ke
r;
 
Lu
p
us
P
R
O
, L
up
us
 P
at
ie
nt
 R
ep
or
te
d
 O
ut
co
m
es
; L
up
us
Q
oL
, L
up
us
 Q
ua
lit
y 
of
 L
ife
 q
ue
st
io
nn
ai
re
; m
S
LA
M
, m
od
ifi
ed
 S
ys
te
m
ic
 L
up
us
 A
ct
iv
ity
 M
ea
su
re
; N
S
, n
ot
 s
ho
w
n;
 P
R
O
M
IS
, P
at
ie
nt
 R
ep
or
te
d
 
O
ut
co
m
es
 M
ea
su
re
m
en
t 
In
fo
rm
at
io
n 
S
ys
te
m
 it
em
-b
an
k;
 S
D
I, 
Th
e 
S
ys
te
m
ic
 L
up
us
 In
te
rn
at
io
na
l C
ol
la
b
or
at
in
g 
C
lin
ic
s/
A
m
er
ic
an
 C
ol
le
ge
 o
f R
he
um
at
ol
og
y 
(A
C
R
) D
am
ag
e 
In
d
ex
; S
F3
6,
 M
ed
ic
al
 O
ut
co
m
es
 
S
tu
d
y 
S
ho
rt
-F
or
m
 3
6;
 S
LA
Q
, S
ys
te
m
ic
 L
up
us
 A
ct
iv
ity
 Q
ue
st
io
nn
ai
re
; S
LE
D
A
I, 
S
ys
te
m
ic
 L
up
us
 E
ry
th
em
at
os
us
 D
is
ea
se
 A
ct
iv
ity
 In
d
ex
; S
LI
C
C
, S
ys
te
m
ic
 L
up
us
 In
te
rn
at
io
na
l C
ol
la
b
or
at
in
g 
C
lin
ic
s.
Ta
b
le
 1
 
C
on
tin
ue
d
Patient reported outcomes Measurement Information system
Significant ceiling effects were reported in most domains 
of the 29-item profile,49 while no floor or ceiling effects 
were observed among 14 Computer Adaptive Tests 
(CATs).50 PROMIS measures had good internal consist-
ency and test–retest reliability, although the internal 
consistency of the PROMIS CATs remains to be estab-
lished. PROMIS scores correlated strongly (r>0.6) with 
other HRQoL instruments across comparable domains 
and weakly to moderately (r≤0.6) across divergent 
domains.49–52 Correlations with disease activity indices, 
physician global assessment, damage and physical activity 
(using an accelerometer) were mostly weak (<0.3).50–52 
Patients with SLE scored 0.5 SD or worse than the 
general population across most domains.49–53 Longitu-
dinal responsiveness and MIDs have not been published. 
While PROMIS measures have been translated into many 
other languages including Spanish and Chinese, addi-
tional studies are needed to validate PROMIS measures 
in non-English-speaking patients with SLE.50 PROMIS 
measures remain to be used in RCTs.
Functional Assessment of Chronic Illness therapy-Fatigue
We found only one study that reported the measure-
ment properties of FACIT-Fatigue in patients with SLE. 
The measure was found to have good internal consist-
ency; however, the test–retest reliability and the floor 
and ceiling effects are currently unknown.54 FACIT-Fa-
tigue had moderate-high correlations (r=0.5–0.8) with 
SF36, brief pain inventory and patient global assessment, 
but poor correlations with disease activity and physi-
cian global assessments (r=0.1–0.3). Cross sectionally, 
FACIT-Fatigue has good discrimination between remis-
sion-mild versus moderate disease activity (0.52 SDs) but 
not between moderate versus severe disease activity (0.24 
SDs). The measure was responsive to clinical improve-
ments (SRM=0.69) but not clinical deteriorations. The 
measure was responsive to improvements (SRM=0.82) 
and deteriorations (SRM=0.53) in patient global assess-
ment. Distribution and anchor-based estimates suggested 
an MID range of 3–6 points, which is consistent with liter-
ature reports of 3–4 points for patients with rheumatoid 
arthritis or cancer.
We identified three papers that used FACIT-Fatigue in 
an RCT setting (table 4). In all three, the intervention led 
to statistically non-significant improvements in disease 
activity. Two studies reported a change in FACIT-Fatigue 
scores from baseline that was ≥MID (4 points); however, 
only one study reported between-arm differences that 
were ≥MID.
euroQol-5d
We found only one study that reported the measurement 
properties of EQ5D in patients with SLE.55 No floor or 
ceiling effects were observed. Related domains on the 
EQ5D and SF36 correlated strongly (r=0.60), whereas 
unrelated domains showed weak-moderate correlation. 
Disease activity and damage showed weak correlation 
Izadi Z, et al. Lupus Science & Medicine 2018;5:e000279. doi:10.1136/lupus-2018-0002796
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with EQ5D domains (r<0.22). The mean scores differed 
significantly across categories of disease activity but not 
damage. The measure showed poor responsiveness to 
self-reported change in health (SRMs ranged from 0.08 to 
0.27 in patients who deteriorated and from 0.35 to 0.43 in 
patients who improved) but was not responsive to longi-
tudinal changes in disease activity (SRM=0.01 in patients 
who deteriorated and 0.12 in patients who improved). 
SLE-specific MIDs have not been reported. EQ5D was 
shown to have good construct and criterion validity in a 
group of Chinese-speaking patients with SLE.56
EQ5D was used in one RCT that met our inclusion 
criteria. In this study, the intervention led to statistically 
non-significant improvements in disease activity. While 
changes in EQ5D from baseline were ≥MID in one of 
the intervention arms, between-arm differences did not 
reach MID (table 4).
lupus Quality of life
Some domains were found to have significant floor and 
ceiling effects, including intimate relationships and plan-
ning.12 57 The measure was found to have good internal 
consistency and test–retest reliability. LupusQoL had 
strong correlations with SF36 across comparable domains 
(r>0.6) and weak correlations with age, disease dura-
tion, disease activity and damage across all domains 
(r<0.30).12 17 58–61 Scores differed significantly across cate-
gories of disease activity and damage in all domains except 
fatigue and intimate relationships.58 60 The effect size has 
not been reported. SRMs were poor in most domains 
and inconsistent (poor to moderate) across different 
anchors.57 59 SLE-specific MIDs derived using the anchor-
based approach ranged from 2.4 to 8.7 for deteriorations 
and from 3.5 to 7.3 for improvements.17 MIDs using distri-
bution-based approaches based on 0.5 SD ranged from 
12.9 to 16.7. Measurement properties of the LupusQoL 
have been examined and published in Chinese-speaking, 
Farsi-speaking, French-speaking, Italian-speaking, Span-
ish-speaking and Turkish-speaking populations.62–70 A 
version adapted and validated for a US population is also 
available.13
We identified one RCT that used LupusQoL; however, 
the results have not been published.39
lupus Patient reported outcomes
The measure was found to have significant floor effects 
in satisfaction with medical care; data on ceiling effects 
were inconclusive, with one study reporting no ceiling 
effects and another reporting significant ceiling effects 
in all domains except coping.71 72 Good internal consist-
ency and test–retest reliability were reported in most 
domains.71–73 Procreation and satisfaction with care had 
the lowest ICCs. Moderate-strong correlations (r≥0.5) 
were reported with the SF36 across comparable domains, 
while correlations with disease activity, physician global 
assessment, damage and flare were weak-moderate 
(r≤0.50).71–73 In cross-sectional analyses, significant asso-
ciations were reported with categories of patient-reported 
Izadi Z, et al. Lupus Science & Medicine 2018;5:e000279. doi:10.1136/lupus-2018-0002798
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health status across all domains except social support, 
coping, satisfaction with medical care and procreation. 
Lupus symptom scores and pain/vitality scores differ-
entiated among patients with flare/active disease and 
those without; however, estimates of effect size were not 
reported.72 73 Scores changed significantly in response to 
longitudinal changes in patient-reported health (across 
seven domains), physician global assessment (across six 
domains) and flare (across five domains); however, SRMs 
have not been reported.71 No data are currently available 
on MIDs. The instrument has been validated in several 
languages, including Chinese, French, Italian, Japanese, 
Spanish, Tagalog and Turkish.74–82 The instrument has 
not been used in an RCT.
lupus Impact tracker
The instrument had good internal consistency and test–
retest reliability83–85; however, no data are available on 
floor and ceiling effects. Moderate-strong correlations 
(r≥0.40) were reported with patient-reported HRQoL 
measures, and correlations with disease activity, damage 
and physician global assessment were mostly weak 
(r≤0.31).83 84 86 The mean scores differed significantly 
across dichotomised categories of disease activity, disa-
bility, socioeconomic status, age, race, education and 
marital status83–86; estimates of effect size have not been 
reported. Scores changed significantly in response to 
longitudinal changes in patient-reported outcomes or 
disease activity.83–86 Data on SRMs were contradictory 
and further research is warranted. One study suggested 
that the measure was responsive to clinical improve-
ments (SRM=0.69) but not to clinical deteriorations 
(SRM=0.20).87 MIDs range from 2 to 4 for clinical dete-
riorations and an MID of 28 points has been reported 
for clinical improvements.83 87 The instrument has been 
validated in several languages, including German, Italian, 
Spanish, Swedish and French.88 The instrument has not 
been used in an RCT setting.
dIsCussIon
In this review, we compared the measurement prop-
erties of 7 patient-reported HRQoL instruments in 
English-speaking adult patients with SLE using data 
from 25 validation studies and 26 drug RCTs. Overall, 
we found comparable measurement properties between 
the disease-specific measures, the SF36 and the PROMIS 
measures, but few measures aside from the SF36 have 
been incorporated into clinical trials. In general, instru-
ments had good validity but poor-moderate respon-
siveness to change over time. Cultural adaptability and 
responsiveness of the PROMIS measures remain to be 
reported. In RCTs, clinically important improvements 
were reported in SF36 scores from baseline; however, 
between-arm differences were frequently non-significant 
and non-important, implying the SF36 is not responsive 
to interventions.
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Despite the validation of the PROMIS item-bank and the 
disease-specific instruments in SLE, SF36 frequently has 
been the only patient-reported outcome in RCTs. Several 
prior publications have called for standardisation of 
instruments to measure HRQoL in SLE research to enable 
comparison between studies and encouraged SF36 use as 
it is internationally recognised and well-validated across 
multiple conditions.89 The 1995 Systemic Lupus Inter-
national Collaborating Clinics Workshop recommended 
SF36 for measuring HRQoL in patients with SLE.16 It was 
also recommended by Outcome Measures in Rheuma-
tology IV for assessment in RCTs and longitudinal obser-
vational studies in SLE.17 Our findings do not support the 
use of SF36 as the key measure moving forward and show 
that the SF36 is not particularly responsive in SLE. Despite 
its extensive validation, the measure’s test–retest reli-
ability and known-group validity using effect size remain 
to be reported and may provide further insight into the 
measure’s responsiveness. Generally, instruments found 
to discriminate among clinically distinct groups are also 
found to be responsive to change.90 PROMIS measures 
provided the strongest evidence for known-group validity, 
indicating they may be more sensitive to change over 
time; however, this remains to be tested. Our findings also 
demonstrate that the disease-specific measures had good 
validity and reliability and were equally or more respon-
sive to change than the SF36. As the field of clinical trials 
in SLE evolves, guidelines should be revised to encourage 
use of a broader range of validated HRQoL measures in 
clinical research to improve study designs. Incorporating 
disease-specific HRQoL measures as endpoints is also 
important in providing patient-centric care to improve 
outcomes pertinent to patients with SLE.4
Consistent with a prior review of patient-reported 
outcomes in lupus clinical trials,4 data from RCTs that 
used the SF36 show that longitudinal changes were 
clinically important regardless of assignment to phar-
macological intervention. In contrast, between-arm 
differences were mostly non-important and non-signifi-
cant. One interpretation of this finding is that non-phar-
macological interventions associated with RCTs (such as 
routine monitoring of adverse events, improved access 
to health services, provision of multidisciplinary care, 
use of background medication, provision of health-re-
lated educational material and improved patient–physi-
cian dialogue) may have a greater impact on constructs 
measured by the SF36 than pharmacological interven-
tions that specifically target clinical outcomes. The 
observation that non-pharmacological approaches can 
improve HRQoL is supported by prior research89 and 
suggests that the combinations of pharmacological and 
non-pharmacological therapies may have an additive 
(or perhaps synergistic) effect on improving HRQoL. 
Selection bias may be another plausible explanation for 
clinically important improvements in HRQoL among 
patients assigned to placebo in RCTs. Strict inclusion 
criteria often mean that patients enrolled in RCTs are 
generally healthier and better-informed than the general 
SLE population and more likely to experience further 
improvements in self-perceived health. Finally, there are 
observations that the MID determined through anchor-
based methods seen in validation studies may differ 
from MIDs seen in RCTs.90 As evidence accumulates in 
RCTs, the observed changes in HRQoL measures based 
on effective treatments provide a valuable source of data 
on responsiveness and MIDs. Therefore, it is important 
that clinical trial literature in SLE is reviewed for older 
instruments such as the SF36 and synthesised for newer 
instruments to further support the evidence base on 
responsiveness and MID for interpreting HRQoL data.
While the validity of this literature review is strength-
ened by the inclusion of validation studies and RCTs, 
this study has some limitations. First, an assessment of 
the quality of the studies identified from the literature 
search was not conducted, so as not to limit our search. 
Second, HRQoL measures that had few publications were 
not prioritised and therefore not included in the indepth 
review. Third, we did not evaluate measurement proper-
ties in non-English-speaking SLE populations.
In conclusion, SLE is a condition associated with high 
unmet need and considerable burden to patients. SF36, 
PROMIS, LupusQoL and LIT have the strongest evidence 
for validity and as such are suitable for use in SLE RCTs; 
however, few measures aside from the SF36 have been 
incorporated into clinical trials. SRMs were inconsis-
tent across different anchors and generally poor in all 
instruments with data for analysis. In RCTs, between-arm 
differences in SF36 scores were frequently non-significant 
and non-important. This review highlights the impor-
tance of incorporating a broader range of SLE-specific 
HRQoL measures in RCTs and warrants further research 
that focuses on longitudinal responsiveness and cultural 
adaptability of newer instruments such as the PROMIS 
item-bank.
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